激素受体阳性晚期乳腺癌内分泌联合治疗的新进展  

Advances in Endocrine Combination Therapy on Hormone-receptor-positive Advanced Breast Cancer

作　　者：程星宇[1] 徐佳[1] 刘磊[1] 王安安[1] 罗永辉[1] CHENG Xingyu XU Jia LIU Lei WANG An＇an LUO Yonghui(Department of Breast Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330000, Chin)

机构地区：[1]南昌大学第二附属医院乳腺外科,南昌330000

出　　处：《肿瘤防治研究》2017年第10期706-709,共4页Cancer Research on Prevention and Treatment

摘　　要：激素受体阳性晚期乳腺癌作为一种难以治愈的异质性恶性肿瘤,严重影响女性的健康与生命。肿瘤生物学行为的变化及其耐药性问题使内分泌后续治疗的临床疗效不尽如人意。近年来,随着内分泌耐药细胞内信号转导通路机制的研究,许多靶向药物被联合应用于临床实践,可明显改善患者无疾病进展期,提高生活质量,为晚期乳腺癌后续内分泌治疗药物的选择提供了更多的证据。本文就晚期乳腺癌内分泌联合治疗的最新进展作一综述。Hormone-receptor-positive advanced breast cancer is an incurable heterogeneous malignant tumor, seriously affecting the health and life of women. The clinical benefit of endocrine follow-up treatment is unsatisfactory due to the changes of tumor biological behavior and its drugs resistance. In recent years, many agents targeting the intracellular signaling pathways associated with endocrine resistance are in development and significantly improve the patients＇ progression-free survival （PFS） and quality of life, providing more evidence for follow-up endocrine therapy on advanced breast cancer. This article reviews the latest advances in endocrine combination therapy on advanced breast cancer.

关 键 词：晚期乳腺癌 内分泌治疗 芳香化酶抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]